Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 infection may trigger poor asthma control in children

Christine C. Chou, MD\textsuperscript{a}, Tricia Morphew, MSc\textsuperscript{b}, Louis Ehwerhemuepha, PhD\textsuperscript{c}, and Stanley P. Galant, MD\textsuperscript{d,e}

Respiratory viral infections are major triggers of asthma exacerbations, including coronaviruses.\textsuperscript{1} It was therefore unexpected that asthmatic children have not experienced increased exacerbations during the COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) virus.\textsuperscript{2} In fact, we previously found a dramatic reduction in asthma morbidity after mid-March 2020 compared with previous years, which was plausibly associated with fewer respiratory viral illnesses during stay-at-home measures.\textsuperscript{3} Another hypothesis is that SARS-CoV-2 itself is not a major asthma trigger, as suggested by two recent studies. Ruano et al\textsuperscript{4} compared 29 asthmatic children with probable COVID-19 with 183 non-COVID-19 cases and found no significant differences in oral corticosteroid (OCS) use or asthma-related emergency department (ED) visits or hospitalizations but significantly increased use of short-acting β-agonists (SABA) and asthma controllers. More recently, Amat et al\textsuperscript{5} found no change in asthma control or FEV\textsubscript{1} in 51 asthmatic children who developed PCR-positive COVID-19. These studies suggest that COVID-19 in asthmatic children does not worsen asthma outcomes, but the studies were limited by small sample sizes and/or the lack of a comparison group. Our study objective was to establish whether the SARS-CoV-2 virus is an asthma trigger resulting in poor asthma control.

We identified 61,916 asthmatic children aged 2 to 17.9 years in the Cerner Real-World Data,\textsuperscript{6} encompassing 108 health systems across the United States, as having received a SARS-CoV-2 PCR test from March 2020 through February 2021. This encapsulates the original strains of SARS-COV-2 and possibly variants \( \alpha \), \( \beta \), and \( \gamma \), which were designated as variants of concern in December 2020, but not variants being monitored until September 2021 according to the Centers for Disease Control and Prevention.\textsuperscript{7} Asthma control was measured by OCS controllers, combination therapy

| Characteristic                  | Overall (n = 61,916) | COVID\textsuperscript{−} (n = 54,170) | COVID\textsuperscript{+} (n = 7,746) | \( P \) |
|--------------------------------|---------------------|--------------------------------------|------------------------------------|-----|
| Age at baseline,\textsuperscript{a} y (means [SD]) | 10.3 (4.5) | 10.2 (4.6) | 11.2 (4.4) | <.001\|<
| 2-4                           | 13.5%    | 14.2%    | 9.2%     | <.001\|<
| 5-11                          | 42.3%    | 42.8%    | 39.1%    |        |
| 12-17                         | 44.1%    | 43.0%    | 51.7%    |        |
| Sex, male                     | 43.2%    | 43.1%    | 43.5%    | .495   |
| Race or ethnicity             |               |                                     |                                    |       |
| American Indian or Alaskan Native | 1.1%    | 1.0%    | 1.3%    |        |
| Asian                         | 1.3%     | 1.3%    | 1.3%    |        |
| Black or African American     | 20.9%    | 20.9%   | 21.2%   |        |
| Hispanic                      | 2.8%     | 2.5%    | 4.9%    |        |
| Native Hawaiian or other Pacific Islander | 0.2%    | 0.2%    | 0.3%    |        |
| White                         | 58.0%    | 58.7%   | 53.7%   |        |
| Other or unknown              | 12.5%    | 12.3%   | 13.9%   |        |
| Asthma, high-risk\|\( \dagger \) | 7.2%    | 7.3%    | 6.6%    | .029\|<
| Asthma pharmacotherapy         |               |                                     | .186                               |
| (before 3 mo)                 |               |                                     |                                    |       |
| No reliever or controller medications | 84.8%  | 84.8%   | 84.7%   |        |
| Reliever(s) only              | 7.2%     | 7.1%    | 7.7%    |        |
| Controller, monotherapy       | 6.6%     | 6.7%    | 6.2%    |        |
| Controllers, combination therapy | 1.4%  | 1.4%    | 1.4%    |        |

Other includes Middle Eastern or North African, Abenaki, Afghanistani, Bahamian, Bangladeshi, European, mixed racial group, Pakistani, data refused, not asked, not stated.

\( a \)Baseline defined as date of COVID test.

\( \dagger \)P indicates significance of distributional difference between COVID\textsuperscript{−}/COVID\textsuperscript{+} groups based on \( \chi^2 \) test for categorical and ANOVA for age on a continuous scale (\( P < .05 \)).

\( \dagger \)High risk is defined by any of the following morbidity events in past year: two or more emergency department visits, two or more oral corticosteroid fills, or one or more hospitalization.

average age, Hispanic ethnicity, and non—high-risk asthma compared with those who were PCR-negative (COVID\textsuperscript{−}) (\( P < .05 \) (Table I). As expected from our previous study,\textsuperscript{3} COVID\textsuperscript{+} children showed significant reductions in asthma-related hospitalizations, ED visits, OCS fill rates, and SABA use in the 6 months after PCR compared with 6 months before PCR testing (\( P < .001 \) (Figure 1). However, COVID\textsuperscript{+} asthmatic patients showed significant increases in ED visits (incidence rate ratio [IRR] = 1.17; \( P = .018 \) and OCS fills (IRR = 1.23; \( P < .001 \) in the post-PCR period, and only slight increases in hospitalizations (IRR = 1.13; \( P = .336 \)) or SABA use (IRR = 1.02; \( P = .861 \)) after infection. However,
these slight increases in hospitalization and SABA fill rates in the COVID+ group after infection contrast starkly with the significant decrease in the COVID− group after PCR testing. In the 6 months before SARS-CoV-2 PCR testing, no significant differences were seen in either the COVID+ or COVID− cohorts for the ED rate, hospitalization rate, and SABA fill rates. The OCS fill rate was slightly lower in the COVID+ group compared with the COVID− group (IRR = 0.88; P = .002). Conversely, during the 6 months after SARS-CoV-2 testing, COVID+ patients had significantly higher morbidities in all measures compared with those who were COVID− (ED rate [IRR = 1.73; P < .001], hospitalization rate [IRR = 4.81; P < .001], OCS fill rate [IRR = 1.50; P < .001], and SABA fill rate [IRR = 1.66; P < .001]) (Figure 1).

Our data demonstrate that although asthma outcomes were again improved for those who tested negative for SARS-COV-2 PCR, asthmatic children who were given a definitive diagnosis of COVID-19 have worse asthma control in the first 6 months after infection. The overall improvement in asthma control during the pandemic is hypothesized to result from hygiene and public health measures, and/or decreased exposures to particulate matter and viral triggers. In our study, the effect of COVID-19 on asthma became discernable when we compared children who were PCR-positive with those who were PCR-negative in the post-6 month period, because all metrics showed highly significant differences with this comparison. Thus, the asthma-triggering effect of SARS-CoV-2 was likely masked by the overall decrease in asthma exacerbations during the stay-at-home measures when other asthma triggers were less present in the community.

The apparent protective effect against SARS-CoV-2 infection in high-risk asthma patients could be attributed to several factors. Increased inhaled corticosteroid use and/or atopic status with reduced expression of angiotensin-converting enzyme-2, an entry receptor for SARS-COV-2, may be possible explanations. The effects of medication and atopy are out of the scope of this brief communication and will be further explored in full-length articles along with analyses of other select variables such as age, race, and regional or temporal factors. A potential limitation of our study is that the retrospective design limits the proof of causation between SARS-CoV-2 and poor asthma control. However, the strengths of our study are the large sample representing diverse ethnic populations across the United States in multiple health care systems and the inclusion of a comparison group.

**Acknowledgments**

We thank the CSO Small Grants Program of the CHOC Children’s Research Institute at the CHOC Children’s Hospital of Orange County for their support of this study.
This work was supported by the CHOC Research Institute at CHOC Children’s Hospital of Orange County (Grant 16993001).

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication January 12, 2022; revised March 16, 2022; accepted for publication April 5, 2022.

Available online April 26, 2022.

Corresponding author: Christine C. Chou, MD, Department of Pediatrics, Children’s Hospital of Orange County, 1201 W La Veta Ave, Orange, Calif 92868. E-mail: cchou@choc.org.

REFERENCES

1. Abe N, Yasudo H, Fukano R, Nakamura T, Okada S, Wakiguchi H, et al. Multi-season analyses of causative pathogens in children hospitalized with asthma exacerbation. Pediatr Allergy Immunol 2019;30:724-31.

2. Timberlake DT, Strothman K, Grayson MH. Asthma, severe acute respiratory syndrome coronavirus-2 and coronavirus disease 2019. Curr Opin Allergy Clin Immunol 2021;21:182-7.

3. Gujon OL, Morphew T, Ehwerhemuepha L, Galant SP. Evaluating the impact of coronavirus disease 2019 on asthma morbidity: a comprehensive analysis of potential influencing factors. Ann Allergy Asthma Immunol 2021;127:91-9.

4. Ruano FJ, Somoza Álvarez ML, Haroun-Díaz E, Vazquez de la Torre M, Lopez Gonzalez P, Prieto-Moreno A, et al. Impact of the COVID-19 pandemic in children with allergic asthma. J Allergy Clin Immunol Pract 2020;8:3172-3174.e1.

5. Amat F, Delaisi B, Labbé JP, Leonardí J, Houdouin V. Asthma may not be a risk factor for severe COVID-19 in children. J Allergy Clin Immunol Pract 2021;9:2478-9.

6. Ehwerhemuepha L, Gasperino G, Bischoff N, Taraman S, Chang A, Feaster W. HealtheDataLab - a cloud computing solution for data science and advanced analytics in healthcare with application to predicting multi-center pediatric readmissions. BMC Med Inform Decis Mak 2020;20:115.

7. Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. Accessed December 1, 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html.

8. Lipworth B, Kuo CR, Lipworth S, Chan R. Inhaled Corticosteroids and COVID-19. Am J Respir Crit Care Med 2020;202:899-900.

9. Jackson DI, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol 2020;146:203-206.e3.